Smith & Nephew PLC (SN.)

Industry Medical Devices
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

1,237.50p

Buy

1,238.00p

arrow-down-23.50p (-1.86%)

Prices updated at 21 Apr 2026, 15:38 BST
| Prices minimum 15 mins delay
|
Prices in GBX
Smith & Nephew PLC designs, manufactures, and markets orthopedic devices and wound-care solutions. Its products include knee replacements, hip implants, nails, fixation devices, arthroscopy tools and others.
FTSE All-Share
arrow-down-0.67%
LSE
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Medical Devices
Chairman
Mr. Rupert C Soames OBE
CEO
Mr. Deepak S. Nath
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
16,988
Head office
Hatters Lane
Watford
United Kingdom
WD18 8YE
mobile
+44 1923477100
letter
helen.barraclough@smith-nephew.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Ms. Angie Risley
Non-Executive Director, Senior Independent non-executive director
-
Mr. Rupert C Soames OBE
Non-Executive Director, Chairman
-
Mr. David P King
Non-Executive Director
-
Mr. Marc E. Owen
Non-Executive Director
-
Mr. Simon Jonathan Lowth
Non-Executive Director
-
Mr. Jeremy Kim Maiden
Non-Executive Director
-
Dr. Garheng Kong, M.D.,PhD
Non-Executive Director
-
Ms. Joanna Christine Hallas
Non-Executive Director
-
Dr. Katarzyna Mazur-Hofsaess, PhD
Non-Executive Director
-
Ms. Therese Esperdy
Non-Executive Director
-
Ms. Sybella Jane Stanley
Non-Executive Director
-
Dr. John Ma
Non-Executive Director
-
Mr. John Terence Rogers
Executive Director, Chief Financial Officer
-
Mr. Deepak S. Nath
Executive Director, Chief Executive Officer
-

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
Principal Global Investors LLC36,750,967
Massachusetts Financial Services Company23,076,056
Vanguard22,176,483
MFS International Intrinsic Value Fd14,856,668
BlackRock Fund Advisors14,571,803

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
23 Mar 2026Transfer in
23 Mar 2026Sale
23 Mar 2026Transfer in
23 Mar 2026Sale
23 Mar 2026Transfer in
23 Mar 2026Sale
23 Mar 2026Transfer in
23 Mar 2026Sale
16 Jan 2026Purchase
18 Nov 2025Purchase
11 Nov 2025Sale
11 Nov 2025Transfer in
07 Nov 2025Purchase
06 Nov 2025Purchase
22 Aug 2025Purchase
22 Aug 2025Purchase
22 Aug 2025Purchase
22 Aug 2025Purchase
22 Aug 2025Purchase
22 Aug 2025Purchase
Please note that past performance is not a reliable indicator of future returns.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2026 Morningstar. All rights reserved.